(Q37678409)

21 August 2017

1 reference

title

The virosomal adjuvanted influenza vaccine (English)

1 reference

21 August 2017

1 reference

Selma Calcagnile

1

1 reference

21 August 2017

Gian Vincenzo Zuccotti

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

Expert Opinion on Biological Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

191-200

1 reference

Impact of influenza on mortality in relation to age and underlying disease, 1967-1989.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Serious morbidity and mortality associated with influenza epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

The impact of influenza on the health and health care utilisation of elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

The unmet need in the elderly: designing new influenza vaccines for older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Influenza vaccination in elderly people

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Antibody response to influenza vaccination in the elderly: a quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Influenza and the rates of hospitalization for respiratory disease among infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Population-wide benefits of routine vaccination of children against influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Vaccination and autoimmune disease: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Inactivated influenza virus vaccines in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Antibody induction by influenza vaccines in the elderly: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

A one-size-fits-all flu vaccine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Inflexal V--the influenza vaccine with the lowest ovalbumin content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Influenza virosomes enhance class I restricted CTL induction through CD4+ T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

The virosome concept for influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Influenza vaccination in patients with cirrhosis and in liver transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Virosome influenza vaccine in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Humoral and Cellular Response to Influenza Vaccine in HIV-Infected Children With Full Viroimmunologic Response to Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903431014

10.1517/14712590903431014

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference